BCPEMI
KIN

Bain Capital Public Equity Management II’s Kindred Biosciences, Inc. KIN Stock Holding History

Bain Capital Public Equity Management II’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-891,500
Closed -$4.43M – 75
2021
Q1 		$4.43M Buy
+891,500
New +$4.31M 0.18% 47

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Bain Capital Public Equity Management II's KIN Position: Q2 2021 in Review

Bain Capital Public Equity Management II sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 891,500 shares — an estimated $4.43M sold.

Bain Capital Public Equity Management II first reported a position in KIN in Q1 2021 and held it in 1 quarter. The position peaked at $4.43M in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • Bain Capital Public Equity Management II reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bain Capital Public Equity Management II sold 891,500 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $4.43M.
  • Bain Capital Public Equity Management II first reported a position in Kindred Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Bain Capital Public Equity Management II's Kindred Biosciences, Inc. position peaked at $4.43M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Bain Capital Public Equity Management II's 13F filing for Q2 2021, filed 16 Aug 2021.